Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026)
Upstream Bio's (UPB) quarterly Income from Continuing Operations came in at 61786000.0 in Q1 2026, down 77.23% year-on-year from 271290342.32 in Q1 2025, and up 69.83% quarter-over-quarter from 204790000.0 in Q4 2025.
Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Upstream Bio's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 61786000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 77.23% year-over-year to 61786000.0 in Q1 2026; TTM through Mar 2026 was 483992000.0, a 146.9% decrease from a year earlier, with the FY2025 full-year figure at 305705000.0, down 123.29% from the prior year.
- Income from Continuing Operations improved to 61786000.0 in Q1 2026 per UPB's latest filing, from 204790000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7859000.0 in Q3 2023 and bottomed at 204790000.0 in Q4 2025.
- The 4-year median for Income from Continuing Operations is 52506000.0 (2023), against an average of 68676090.91.
- Biggest YoY gain for Income from Continuing Operations was 76.19% in 2024; the steepest drop was 549.96% in 2024.
- Year by year, Income from Continuing Operations stood at 52506000.0 in 2023, then sank by 76.19% to 92508000.0 in 2024, then tumbled by 121.38% to 204790000.0 in 2025, then surged by 69.83% to 61786000.0 in 2026.
- Per Business Quant, the three latest UPB Income from Continuing Operations figures stand at 61786000.0 (Q1 2026), 204790000.0 (Q4 2025), and 133269000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Upstream Bio | 347.73 Mn | 347.73 Mn | -3.94 Mn | -61.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.79 Mn |
| Dec 31, 2025 | -204.79 Mn |
| Sep 30, 2025 | -133.27 Mn |
| Jun 30, 2025 | -84.15 Mn |
| Mar 31, 2025 | -34.86 Mn |
| Dec 31, 2024 | -92.51 Mn |
| Sep 30, 2024 | -51.08 Mn |
| Jun 30, 2024 | -17.57 Mn |
| Mar 31, 2024 | -15.06 Mn |
| Dec 31, 2023 | -52.51 Mn |
| Sep 30, 2023 | -7.86 Mn |